155 related articles for article (PubMed ID: 15766567)
1. Covalent modification of human homeodomain interacting protein kinase 2 by SUMO-1 at lysine 25 affects its stability.
Gresko E; Möller A; Roscic A; Schmitz ML
Biochem Biophys Res Commun; 2005 Apr; 329(4):1293-9. PubMed ID: 15766567
[TBL] [Abstract][Full Text] [Related]
2. Role of the SUMO-interacting motif in HIPK2 targeting to the PML nuclear bodies and regulation of p53.
Sung KS; Lee YA; Kim ET; Lee SR; Ahn JH; Choi CY
Exp Cell Res; 2011 Apr; 317(7):1060-70. PubMed ID: 21192925
[TBL] [Abstract][Full Text] [Related]
3. Regulation of homeodomain-interacting protein kinase 2 (HIPK2) effector function through dynamic small ubiquitin-related modifier-1 (SUMO-1) modification.
Hofmann TG; Jaffray E; Stollberg N; Hay RT; Will H
J Biol Chem; 2005 Aug; 280(32):29224-32. PubMed ID: 15958389
[TBL] [Abstract][Full Text] [Related]
4. Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression.
Bon G; Di Carlo SE; Folgiero V; Avetrani P; Lazzari C; D'Orazi G; Brizzi MF; Sacchi A; Soddu S; Blandino G; Mottolese M; Falcioni R
Cancer Res; 2009 Jul; 69(14):5978-86. PubMed ID: 19567674
[TBL] [Abstract][Full Text] [Related]
5. Axin stimulates p53 functions by activation of HIPK2 kinase through multimeric complex formation.
Rui Y; Xu Z; Lin S; Li Q; Rui H; Luo W; Zhou HM; Cheung PY; Wu Z; Ye Z; Li P; Han J; Lin SC
EMBO J; 2004 Nov; 23(23):4583-94. PubMed ID: 15526030
[TBL] [Abstract][Full Text] [Related]
6. Differential interactions of the homeodomain-interacting protein kinase 2 (HIPK2) by phosphorylation-dependent sumoylation.
Sung KS; Go YY; Ahn JH; Kim YH; Kim Y; Choi CY
FEBS Lett; 2005 Jun; 579(14):3001-8. PubMed ID: 15896780
[TBL] [Abstract][Full Text] [Related]
7. HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after nonapoptotic DNA damage.
Di Stefano V; Soddu S; Sacchi A; D'Orazi G
Oncogene; 2005 Aug; 24(35):5431-42. PubMed ID: 15897882
[TBL] [Abstract][Full Text] [Related]
8. Novel homeodomain-interacting protein kinase family member, HIPK4, phosphorylates human p53 at serine 9.
Arai S; Matsushita A; Du K; Yagi K; Okazaki Y; Kurokawa R
FEBS Lett; 2007 Dec; 581(29):5649-57. PubMed ID: 18022393
[TBL] [Abstract][Full Text] [Related]
9. Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1.
Gostissa M; Hengstermann A; Fogal V; Sandy P; Schwarz SE; Scheffner M; Del Sal G
EMBO J; 1999 Nov; 18(22):6462-71. PubMed ID: 10562558
[TBL] [Abstract][Full Text] [Related]
10. High mobility group I (Y) proteins bind HIPK2, a serine-threonine kinase protein which inhibits cell growth.
Pierantoni GM; Fedele M; Pentimalli F; Benvenuto G; Pero R; Viglietto G; Santoro M; Chiariotti L; Fusco A
Oncogene; 2001 Sep; 20(43):6132-41. PubMed ID: 11593421
[TBL] [Abstract][Full Text] [Related]
11. The human protein kinase HIPK2 phosphorylates and downregulates the methyl-binding transcription factor ZBTB4.
Yamada D; Pérez-Torrado R; Filion G; Caly M; Jammart B; Devignot V; Sasai N; Ravassard P; Mallet J; Sastre-Garau X; Schmitz ML; Defossez PA
Oncogene; 2009 Jul; 28(27):2535-44. PubMed ID: 19448668
[TBL] [Abstract][Full Text] [Related]
12. Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells.
Puca R; Nardinocchi L; Givol D; D'Orazi G
Oncogene; 2010 Aug; 29(31):4378-87. PubMed ID: 20514025
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of homeodomain-interacting protein kinase 2 on the aorta-gonad-mesonephros hematopoiesis.
Ohtsu N; Nobuhisa I; Mochita M; Taga T
Exp Cell Res; 2007 Jan; 313(1):88-97. PubMed ID: 17064687
[TBL] [Abstract][Full Text] [Related]
14. Molecular cloning of the cDNA of canine homeodomain-interacting protein kinase 2.
Lee SY; Chung JY; Shin IS; Choi EW; Hwang CY; Youn HY; Han HR
J Vet Sci; 2005 Jun; 6(2):141-5. PubMed ID: 15933434
[TBL] [Abstract][Full Text] [Related]
15. SUMO-1 modification increases human SOD1 stability and aggregation.
Fei E; Jia N; Yan M; Ying Z; Sun Q; Wang H; Zhang T; Ma X; Ding H; Yao X; Shi Y; Wang G
Biochem Biophys Res Commun; 2006 Aug; 347(2):406-12. PubMed ID: 16828461
[TBL] [Abstract][Full Text] [Related]
16. Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown.
Puca R; Nardinocchi L; Gal H; Rechavi G; Amariglio N; Domany E; Notterman DA; Scarsella M; Leonetti C; Sacchi A; Blandino G; Givol D; D'Orazi G
Cancer Res; 2008 May; 68(10):3707-14. PubMed ID: 18483253
[TBL] [Abstract][Full Text] [Related]
17. HIPK2 kinase activity depends on cis-autophosphorylation of its activation loop.
Saul VV; de la Vega L; Milanovic M; Krüger M; Braun T; Fritz-Wolf K; Becker K; Schmitz ML
J Mol Cell Biol; 2013 Feb; 5(1):27-38. PubMed ID: 23000554
[TBL] [Abstract][Full Text] [Related]
18. Viral oncoproteins E1A and E7 and cellular LxCxE proteins repress SUMO modification of the retinoblastoma tumor suppressor.
Ledl A; Schmidt D; Müller S
Oncogene; 2005 May; 24(23):3810-8. PubMed ID: 15806172
[TBL] [Abstract][Full Text] [Related]
19. FHL2 mediates p53-induced transcriptional activation through a direct association with HIPK2.
Lee SW; Kim EJ; Um SJ
Biochem Biophys Res Commun; 2006 Jan; 339(4):1056-62. PubMed ID: 16343438
[TBL] [Abstract][Full Text] [Related]
20. Sp100 is important for the stimulatory effect of homeodomain-interacting protein kinase-2 on p53-dependent gene expression.
Möller A; Sirma H; Hofmann TG; Staege H; Gresko E; Lüdi KS; Klimczak E; Dröge W; Will H; Schmitz ML
Oncogene; 2003 Nov; 22(54):8731-7. PubMed ID: 14647468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
